In this video, we explore the costs and benefits of monopolies. We cover how monopolies and patents breed deadweight loss, market inefficiencies, and corruption. But we also look at what would happen if we eliminated patents for industries with high R&D costs, such as the pharmaceutical industry. Eliminating patents in this case may result in less innovation and, specifically, fewer new drugs being created. We also consider some of the tradeoffs of patents and look at alternative ways to reward research and development such as patent buyouts and using prizes to foster innovation.
Microeconomics Course: http://bit.ly/20VablY
Ask a question about the video: http://bit.ly/1RnHxr9
Next video: http://bit.ly/1XMYb62
Help us caption & translate this video!
A monopolist produces less output and sells it at a higher price than a perfectly competitive firm. The monopolist's behavior is costly to the consumers who demand the monopolist's output
Due to the fact that monopolies make lots of profits, it can be used for research and development and to maintain their status as a monopoly.
A monopolist produces less output and sells it at a higher price than a perfectly competitive firm. The monopolists behavior is costly to the consumers who demand the monopolists output .
Due to the fact that monopolies make lots of profits, it can be used for research and development and to maintain their status as a monopoly
stating the positive sides of Monopolies is interesting to me as i am not thoroughly convinced by it , for instance pharmaceutical companies have ways to stretch their monopoly pricing power to as long as 20 years or more. Mylan’s EpiPen patent is just one example. They can change the drug’s packaging or method of administration without clinical benefit and extend their patents. They can also pay off generic drug manufacturers not to bring a generic substitute to market.
When a patent expires, generic drug manufacturers can enter the market. But, prices often still do not come down because of generic drug company monopolies. For that reason, for example, doxycycline’s price increased 90 times in the two years between 2013 and 2015. so its not yet a settle science and we should have discussions about it .
What they said about drug prices dropping to marginal cost when patents expire is no longer true. Recently, generic drug companies have been hiking the prices of generic drugs as well. How can this be if there's no longer a monopoly on the drug patent? Obviously profiteering is the rule of the land, not economics
Aren't generic drugs also regulated by the FDA, thus discouraging and limiting the entry into this industry and giving the ones already available some sort of market power? I'm not sure that was the reason for what u said but yeah, the drug industry is heavily regulated.
There are many reasons for monopoly positions besides patents such as economies of scale or, more often, barriers to entry. Even when a patent expires, there are other causes of monopoly positions left in place. Because the pharmaceutical industry suffers from barriers to entry, drug companies afford to hike prices of drugs whose patents have expired. The economic logic of the monopoly profits still accounts for "the rule of the land", which is making monopoly profits from monopoly positions, secured with political and regulatory means.
It's funny, I've thought about a lot about some of these ideas. I like the idea of different prices for different people, particularly for things like tickets to live entertainment events. They do that to an extent with backstage passes and better seats, but once you get to the nosebleed section scalpers get most of the extra money or, if the show doesn't draw enough people to sell out you either get the scalpers trying to dry up the supply (if it's close) or empty seats. I suspect that, especially since so many arenas can make extra money on concessions once they get people through the door that a carefully constructed auction would work well. I think I'd start with the prime seats, and set an early close for that auction. To encourage people to bid during the auction but still make sure all the seats in that block are sold I'd run it as a series of auctions- say you want to deal with the first row seating. You run an auction, set to end x number of days before the show, you set a reserve and take secret bids. At the end of the auction you sell to any bidders that met the reserve. If you have seats left over, you have a second auction, and set your reserve lower. Repeat as many times as you think it's profitable to do so. Have any tickets that don't meet those reserves available at the door. The idea that the seats might go in an earlier auction should get people to bid early. Do the same for other rows of seating, grouping seats of similar quality together. Ideally the venue, if they are booking you, should be willing to take some risk on selling the last seats at a discount, since they can still make money on concessions. Although there is something oddly democratic about the ticket line for a rock show I suspect that the extra revenue would actually let bands play slightly larger arenas, which would mean more fans would actually get to see the show.
The other place that I'd like to see pricing differences depending on who you are also involves tickets, but not entertainment tickets. The good old parking ticket/traffic ticket is, in some countries, based on your income. Seems like a good idea, since their ideally supposed to discourage bad behaviors. A $75 ticket would ruin some people's monthly budget, but it's not much of a deterrent for someone who is making high six figures. (Or at least make it so tickets increase in price the more of them you get. I remember seeing someone who got a ticket every day for parking illegally. They owned a business nearby. They just considered it a parking fee.
For pharmaceuticals, I do like the X prize model a lot. It seems the other group, besides the government, that might have a vested interest in that would be the HMOs. It would both lower their drug costs and, if they targeted prizes for things that improved their members health at a better price point (a good cholesterol drug instead of paying for heart surgery) it would give them double savings- the problem there would be trying to either to get a bunch of HMO's to chip in evenly based on market share or to figure out what to do when Kaiser suddenly owns the patent on a wonderful new drug and Blue Shield wants to give it to their patients (perhaps a little quid pro quo if Blue Shield comes up with something?
Work out if you need to pay.
When you know your gain you need to work out if you need to report and pay Capital Gains Tax.
You may be able to work out how much tax to pay on your shares.
the same type, acquired in the same company on the same date sold at the same time.
sold other shares in the tax year sold other chargeable assets in the tax year, such as a property you let out claim any reliefs are a company, agent, trustee or personal representative.
Reporting a loss.
The rules are different if you need to report a loss.
Fifth most actively traded share.
Market capital of DKK 206 bn.
Shareholders by geography.
Rest of Europe etc.
Ratings from equity analysts covering the Danske Bank share and consensus earnings estimates.
Selling in special circumstances.
shares you bought at different times and prices in one company shares through an investment club shares after a company merger or takeover employee share scheme shares.
Jointly owned shares and investments.
If you sell shares or investments that you own jointly with other people, work out the gain for the portion that you own, instead of the whole value. There are different rules for investment clubs.
What to do next.